Indeed, VISTA can be overexpressed in immune cells of patients with estrogen receptor-negative, progesterone receptor-negative, human epidermal growth factor receptor 2 (HER2)-positive, triple-negative, and basal-like breast cancers. Here, ERBB2 is linked to breast carcinoma.